Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Prognostic Significance of Re-Induction Necessity Based on Day-14 Residual Disease and Age-Adjusted Consolidation Approaches in Acute Myeloid Leukemia

  • By

  • Abiola Bolarinwa

  • Muhammad Yousuf

  • Aref Al-Kali

  • Hassan B. Alkhateeb

  • Abhishek A. Mangaonkar

  • Antoine N. Saliba

  • Mehrdad Hefazi Torghabeh

  • Aasiya Matin

  • Michelle A. Elliott

  • Mark R. Litzow

  • William J. Hogan

  • Mithun V. Shah

  • Mrinal M. Patnaik

  • Animesh Pardanani

  • Dong Chen

  • Kaaren K. Reichard

  • Rong He

  • Naseema Gangat

  • Ayalew Tefferi

  • Kebede H. Begna

  • September 30, 2026

Share

Original Source(s)

Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia

  • by Abiola Bolarinwa, Muhammad Yousuf, Aref Al-Kali, Hassan B. Alkhateeb, Abhishek A. Mangaonkar, Antoine N. Saliba, Mehrdad Hefazi Torghabeh, Aasiya Matin, Michelle A. Elliott, Mark R. Litzow, William J. Hogan, Mithun V. Shah, Mrinal M. Patnaik, Animesh Pardanani, Dong Chen, Kaaren K. Reichard, Rong He, Naseema Gangat, Ayalew Tefferi, Kebede H. Begna

  • September 30, 2026

Related Content

Parents’ Perspectives on Using Computerized Cognitive Training to Manage Cognitive Late Effects in Children With Cancer: Qualitative Descriptive Study

EQUIPOISE: EQUivalence In Prostate cancer treatment: surgery Or radiotherapy? An Intention-to-treat Survival analysis from real-world Evidence

Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith

SOTIO Biotech’s CSO explains why drug developers should test their weakest assumptions early, how she builds innovative teams, and where ADCs could go next

  • October 12, 2026

  • 9 min